K Pharma,Inc. (JP:4896)

:4896

4896

K Pharma,Inc.

RESEARCH TOOLSreports

Want to see JP:4896 full AI Analyst Report?

K Pharma,Inc. (4896) Price & Analysis

0 Followers

4896 Stock Chart & Stats

¥651.00

¥14.00(2.16%)

At close: Jan 08 4:00 PM EST

¥651.00

¥14.00(2.16%)

Day’s Range― - ―

52-Week Range¥604.00 - ¥949.00

Previous CloseN/A

Volume10.50K

Average Volume (3M)48.08K

Market Cap

¥8.65B

Enterprise Value¥6.37B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.00

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-26.83

Shares Outstanding11,622,600

10 Day Avg. Volume47,520

30 Day Avg. Volume48,080

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)6.05

Price to Sales (P/S)0.00

P/FCF Ratio-8.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proven Revenue Generation (historical)The company produced ¥1.0B revenue and ¥260M net income in 2023, demonstrating it has previously commercialized products or services. This historical profitability shows the business model can generate revenue and supports the structural possibility of returning to commercialization if development or market access improves.

Improving Cash Burn TrendFree cash flow improved modestly in 2025 versus 2024, indicating management has been able to reduce net cash outflows. A sustained downward trend in burn rate lengthens runway, reduces near-term financing urgency, and provides more time to reach development milestones or re-establish revenue streams.

Tangible Asset BaseWith total assets near ¥2.94B the company retains a tangible asset cushion that can be used to support operations, secure financing, or be monetized in stress scenarios. A material asset base improves creditor confidence and provides a structural buffer while the firm pursues R&D or commercialization.

Bears Say

No Recent RevenueRecording zero revenue across 2024–2025 severs internal cash generation and undermines margin sustainability. For a firm dependent on product development, prolonged revenue absence raises execution risk, forces reliance on external capital, and makes long-term operating viability contingent on successful funding or development progress.

Sustained Negative Cash FlowConsistent OCF and FCF near -¥0.9–1.0B per year is a material structural drain on resources. Persistent negative cash flow requires repeated financing, dilutes shareholders, constrains R&D or commercialization spend, and raises risk that milestones cannot be funded without new capital or partner deals.

Eroding Equity And Rising LeverageEquity decline and higher debt-to-equity materially weaken financial flexibility. A smaller capital base and ~1.19x leverage increase refinancing and solvency risk, limit ability to raise non-dilutive capital, and heighten sensitivity to further losses or adverse financing conditions over the medium term.

4896 FAQ

What was K Pharma,Inc.’s price range in the past 12 months?

K Pharma,Inc. lowest stock price was ¥604.00 and its highest was ¥949.00 in the past 12 months.

What is K Pharma,Inc.’s market cap?

K Pharma,Inc.’s market cap is ¥8.65B.

When is K Pharma,Inc.’s upcoming earnings report date?

K Pharma,Inc.’s upcoming earnings report date is May 20, 2026 which is in 17 days.

How were K Pharma,Inc.’s earnings last quarter?

K Pharma,Inc. released its earnings results on Feb 12, 2026. The company reported -¥26.83 earnings per share for the quarter, missing the consensus estimate of N/A by -¥26.83.

Is K Pharma,Inc. overvalued?

According to Wall Street analysts K Pharma,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does K Pharma,Inc. pay dividends?

K Pharma,Inc. does not currently pay dividends.

What is K Pharma,Inc.’s EPS estimate?

K Pharma,Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does K Pharma,Inc. have?

K Pharma,Inc. has 11,622,600 shares outstanding.

What happened to K Pharma,Inc.’s price movement after its last earnings report?

K Pharma,Inc. reported an EPS of -¥26.83 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.422%.

Which hedge fund is a major shareholder of K Pharma,Inc.?

Currently, no hedge funds are holding shares in JP:4896

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

K Pharma,Inc.

K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is based in Minato, Japan.